Business Wire·May 27, 2026, 8:05 AM ET

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Turn Therapeutics announced a peer-reviewed study in the Journal of Dermatological Treatment showing a statistically significant reduction in disease severity for its lead program GX-03 in a murine dermatitis model characterized by IL-36 expression.
The study evaluated GX-03 in a Staphylococcus aureus-induced model where IL-36 protein expression was confirmed following bacterial exposure to establish a relevant inflammatory environment.
Mice treated with GX-03 twice daily for seven days achieved a mean investigator global assessment score of 1.44 compared to 3.00 in untreated controls (p = 0.0003).
No treatment-related adverse effects were observed during the study.
GX-03 is a first-in-class, non-systemic, topical therapy designed to modulate epithelial danger sensing & address IL-36, IL-4, IL-13, & IL-31 signaling through upstream prevention.
The publication serves as the first in a planned series of scientific articles exploring the rationale & non-systemic mechanism of GX-03, which is currently in Phase 2 evaluation for moderate-to-severe atopic dermatitis.
The research was co-authored by Bradley Burnam, CEO of Turn Therapeutics, & Stephen Bresnick, M.D., a physician, researcher, & advisor to the company.